Vo
lu
m
e
5,
Au
gu
st
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
MODERN APPROACHES TO EARLY DIAGNOSIS AND MANAGEMENT OF
ENDOMETRIAL HYPERPLASTIC PROCESSES
Asrankulova D.B., Abduvayitova Sh.A.
Andijan state medical institute, Andijan, Uzbekistan
Abstract:
Endometrial hyperplastic processes represent a group of proliferative conditions
of the endometrium that range from benign glandular-stromal overgrowth to precancerous
atypical hyperplasia. They are considered one of the most significant gynecological
disorders due to their potential progression to endometrial carcinoma. Early diagnosis and
adequate treatment are essential to prevent malignant transformation while maintaining
reproductive potential. Recent advancements in imaging techniques, molecular diagnostics,
and fertility-preserving treatment options have significantly transformed the clinical
approach to endometrial hyperplasia. This article provides a comprehensive overview of the
current strategies for early detection and treatment, emphasizing personalized medicine and
evidence-based management.
Keywords:
Endometrial hyperplasia; atypical hyperplasia; early diagnosis; hysteroscopy;
endometrial biopsy; progestin therapy; levonorgestrel intrauterine system; fertility
preservation; molecular markers; endometrial carcinoma prevention.
Introduction
Endometrial hyperplasia is defined as an abnormal proliferation of the endometrial glands
and stroma, most often associated with prolonged estrogen stimulation unopposed by
progesterone. Clinically, patients present with abnormal uterine bleeding, infertility, or
incidental findings during imaging. The significance of these lesions lies in their potential
for malignant transformation, particularly in atypical cases, which may progress to
endometrial carcinoma in up to 30 percent of patients if left untreated. Modern approaches
to diagnosis and therapy aim to balance effective treatment with preservation of fertility and
quality of life.
Epidemiological data suggest that the incidence of endometrial hyperplasia has been rising
globally, in parallel with increasing rates of obesity and metabolic syndrome. Studies
indicate that nearly 10–15 percent of women presenting with abnormal uterine bleeding in
perimenopausal age are diagnosed with some form of endometrial hyperplasia. The World
Health Organization (WHO) has classified these lesions into non-atypical hyperplasia and
atypical hyperplasia, with the latter being associated with a substantially higher risk of
malignant transformation. In fact, atypical hyperplasia is now often referred to as
endometrial intraepithelial neoplasia (EIN), reflecting its premalignant potential. Reports
suggest that up to 25–30 percent of patients with atypical hyperplasia may progress to
carcinoma if left untreated.
Traditionally, the management of endometrial hyperplasia involved radical surgical
interventions, including hysterectomy, which, while effective in preventing malignant
progression, also resulted in the irreversible loss of fertility. However, over the past two
decades, significant advances have transformed the diagnostic and therapeutic landscape of
this condition. The development of high-resolution transvaginal ultrasonography, saline
Vo
lu
m
e
5,
Au
gu
st
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
infusion sonohysterography, and office-based hysteroscopy has greatly improved the
accuracy of early detection. Moreover, the introduction of molecular diagnostic techniques,
such as immunohistochemistry and genetic profiling, has provided additional tools to assess
malignant potential at an earlier stage.
Parallel to diagnostic innovations, the therapeutic paradigm has shifted toward conservative
and fertility-preserving strategies. Hormonal therapy, particularly the levonorgestrel-
releasing intrauterine system (LNG-IUS), has demonstrated high efficacy in reversing
hyperplastic changes while minimizing systemic side effects. In addition, minimally
invasive hysteroscopic surgery has become a preferred alternative to blind curettage,
offering both diagnostic and therapeutic benefits. These developments have made it possible
to individualize treatment, taking into account the patient’s age, reproductive desires,
comorbidities, and histological subtype of hyperplasia.
In this context, early diagnosis and modern treatment approaches are essential not only for
reducing the burden of abnormal uterine bleeding but also for preventing progression to
endometrial carcinoma. This article aims to review contemporary strategies in the early
detection and management of endometrial hyperplastic processes, highlighting the
integration of advanced diagnostic tools, molecular insights, and innovative treatment
modalities into everyday clinical practice.
Diagnostic Approaches
Transvaginal ultrasound remains the first-line imaging tool for detecting abnormal
endometrial thickening. In premenopausal women, a thickness greater than 12 mm and in
postmenopausal women a thickness above 5 mm should raise suspicion. Saline infusion
sonohysterography improves visualization of focal lesions, while hysteroscopy provides
direct assessment and the opportunity for simultaneous biopsy or resection.
Histopathological examination through endometrial biopsy remains the gold standard for
diagnosis, allowing differentiation between non-atypical and atypical hyperplasia. In
addition, molecular diagnostics such as PTEN, PAX2, KRAS, and mismatch repair gene
analysis are being investigated as predictive markers of progression risk.
Therapeutic Approaches
Medical therapy has become the cornerstone of treatment for non-atypical hyperplasia.
Progestin therapy, whether systemic or local, induces regression in the majority of patients.
The levonorgestrel-releasing intrauterine system (LNG-IUS) has shown superior results
compared to oral progestins, offering high rates of regression with minimal systemic side
effects. Surgical treatment is reserved for resistant cases or patients with atypical hyperplasia.
Hysteroscopic resection is increasingly used as a fertility-sparing option, allowing precise
removal of localized lesions. For women with completed childbearing and recurrent or
atypical disease, hysterectomy remains the definitive therapy. Fertility-preserving
management is particularly relevant for younger patients; combining LNG-IUS therapy with
assisted reproductive technologies has shown promising pregnancy outcomes.
Preventive and Follow-up Strategies
Vo
lu
m
e
5,
Au
gu
st
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
Lifestyle modifications, including weight reduction, management of insulin resistance, and
treatment of metabolic syndrome, significantly decrease recurrence risk. Continuous
monitoring with ultrasound and repeat biopsies is necessary for early detection of relapse or
progression, particularly in women managed conservatively. A multidisciplinary approach
involving gynecologists, endocrinologists, and oncologists is recommended for optimal care.
Discussion
Modern approaches to endometrial hyperplasia highlight a shift from radical interventions to
patient-centered, minimally invasive, and fertility-preserving therapies. Integration of
imaging, histopathology, and molecular biomarkers allows for earlier and more precise
diagnosis. Hormonal therapy, especially with LNG-IUS, offers high efficacy and safety for
non-atypical hyperplasia. In contrast, atypical hyperplasia requires more aggressive
management due to its high malignant potential. Hysteroscopic resection combined with
close follow-up provides a safe alternative to hysterectomy in selected patients. Future
directions include the development of molecular-based prognostic models and targeted
therapies to further refine individualized treatment strategies.
Conclusion
Endometrial hyperplastic processes require timely diagnosis and evidence-based
management to prevent progression to carcinoma. Modern advances in imaging, molecular
pathology, and conservative treatment approaches allow effective disease control while
preserving reproductive potential. The paradigm has shifted toward individualized care,
emphasizing fertility preservation, minimally invasive surgery, and molecular-guided
diagnostics as key elements of modern gynecological practice.
References
1.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of
Tumours of Female Reproductive Organs. 4th edition. Lyon: IARC; 2014.
2.
Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, Voigt LF.
Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009;200(6):678.e1-678.e6.
3.
Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ. Concurrent
endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial
hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106(4):812–819.
4.
Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta
JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial
hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol.
2010;203(6):547.e1-547.e10.
5.
Raffone A, Travaglino A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F.
Endometrial hyperplasia: new concepts in classification, diagnosis, and management.
Biomed Res Int. 2019;2019:4569850.
Pennant ME, Mehta R, Moody P, Hackett G, Prentice A, Sharp SJ, Lakshman R.
Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG.
2017;124(3):404–411.
